Key result
Antihypertensive agents with a favorable metabolic profile, such as calcium channel antagonists, ACE inhibitors, and selective imidazoline receptor agonists, demonstrate a strong rationale for use in arterial hypertension with metabolic syndrome.
Antihypertensive agents with favorable metabolic profiles, such as calcium channel blockers, ACE inhibitors, and selective imidazoline receptor agonists, are recommended for patients with arterial hypertension and metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports preferential use in hypertension with metabolic syndrome; leaves open confirmation in prospective RCTs.
This review summarizes the literature evidence on humoral disturbances in arterial hypertension (AH), as well as on AH interrelationship with individual components of metabolic syndrome (MS). Based on the results of multi-centre randomised trials, the rationale for the use of antihypertensive agents with favourable metabolic profile is demonstrated, in particular, for antagonists of slow calcium channels, angiotensin-converting enzyme inhibitors, and selective imidazoline receptor agonists.
No takes yet. Share an insight, caveat, or question.
Абасова et al. (2011) conducted a review in Arterial hypertension and metabolic syndrome. Antihypertensive agents with favourable metabolic profile (calcium channel antagonists, ACE inhibitors, selective imidazoline receptor agonists) was evaluated. Antihypertensive agents with a favorable metabolic profile, such as calcium channel antagonists, ACE inhibitors, and selective imidazoline receptor agonists, demonstrate a strong rationale for use in arterial hypertension with metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: